Logo image of ALINS.PA

INTRASENSE SAS (ALINS.PA) Stock Fundamental Analysis

EPA:ALINS - Euronext Paris - Matif - FR0011179886 - Common Stock - Currency: EUR

0.247  +0 (+0.82%)

Fundamental Rating

2

ALINS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 12 industry peers in the Health Care Technology industry. ALINS has a bad profitability rating. Also its financial health evaluation is rather negative. ALINS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALINS had negative earnings in the past year.
ALINS had a negative operating cash flow in the past year.
ALINS had negative earnings in each of the past 5 years.
In the past 5 years ALINS reported 4 times negative operating cash flow.
ALINS.PA Yearly Net Income VS EBIT VS OCF VS FCFALINS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1M -2M -3M -4M

1.2 Ratios

ALINS has a Return On Assets of -45.46%. This is in the lower half of the industry: ALINS underperforms 75.00% of its industry peers.
The Return On Equity of ALINS (-73.59%) is worse than 75.00% of its industry peers.
Industry RankSector Rank
ROA -45.46%
ROE -73.59%
ROIC N/A
ROA(3y)-33.5%
ROA(5y)-26.65%
ROE(3y)-81.07%
ROE(5y)-87.01%
ROIC(3y)N/A
ROIC(5y)N/A
ALINS.PA Yearly ROA, ROE, ROICALINS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

With an excellent Gross Margin value of 91.07%, ALINS belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
ALINS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ALINS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y3.44%
ALINS.PA Yearly Profit, Operating, Gross MarginsALINS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

ALINS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALINS has more shares outstanding
ALINS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ALINS has been reduced compared to a year ago.
ALINS.PA Yearly Shares OutstandingALINS.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
ALINS.PA Yearly Total Debt VS Total AssetsALINS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

An Altman-Z score of 1.82 indicates that ALINS is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALINS has a Altman-Z score of 1.82. This is comparable to the rest of the industry: ALINS outperforms 58.33% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that ALINS is not too dependend on debt financing.
ALINS's Debt to Equity ratio of 0.19 is in line compared to the rest of the industry. ALINS outperforms 58.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 1.82
ROIC/WACCN/A
WACC7.44%
ALINS.PA Yearly LT Debt VS Equity VS FCFALINS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M

2.3 Liquidity

A Current Ratio of 1.82 indicates that ALINS should not have too much problems paying its short term obligations.
The Current ratio of ALINS (1.82) is comparable to the rest of the industry.
ALINS has a Quick Ratio of 1.82. This is a normal value and indicates that ALINS is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.82, ALINS is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.82
ALINS.PA Yearly Current Assets VS Current LiabilitesALINS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M

More info and screens

4

3. Growth

3.1 Past

ALINS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.82%.
ALINS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -42.65%.
Measured over the past years, ALINS shows a small growth in Revenue. The Revenue has been growing by 1.53% on average per year.
EPS 1Y (TTM)6.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.22%
Revenue 1Y (TTM)-42.65%
Revenue growth 3Y-1.34%
Revenue growth 5Y1.53%
Sales Q2Q%-44.77%

3.2 Future

Based on estimates for the next years, ALINS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.57% on average per year.
The Revenue is expected to grow by 16.54% on average over the next years. This is quite good.
EPS Next Y0%
EPS Next 2Y17.26%
EPS Next 3Y17.57%
EPS Next 5YN/A
Revenue Next Year-29.35%
Revenue Next 2Y10.07%
Revenue Next 3Y16.54%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALINS.PA Yearly Revenue VS EstimatesALINS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
ALINS.PA Yearly EPS VS EstimatesALINS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALINS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALINS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALINS.PA Price Earnings VS Forward Price EarningsALINS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALINS.PA Per share dataALINS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1 -0.1

4.3 Compensation for Growth

ALINS's earnings are expected to grow with 17.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.26%
EPS Next 3Y17.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALINS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTRASENSE SAS

EPA:ALINS (3/7/2025, 7:00:00 PM)

0.247

+0 (+0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)09-25 2024-09-25
Earnings (Next)03-25 2025-03-25
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.89%
Ins Owner ChangeN/A
Market Cap13.02M
Analysts40
Price Target0.24 (-2.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.59
P/FCF N/A
P/OCF N/A
P/B 2.46
P/tB 9.68
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.04
BVpS0.1
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.46%
ROE -73.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.07%
FCFM N/A
ROA(3y)-33.5%
ROA(5y)-26.65%
ROE(3y)-81.07%
ROE(5y)-87.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y3.44%
F-ScoreN/A
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 222.99%
Cap/Sales 91.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.82
Altman-Z 1.82
F-ScoreN/A
WACC7.44%
ROIC/WACCN/A
Cap/Depr(3y)159.67%
Cap/Depr(5y)249.68%
Cap/Sales(3y)36.91%
Cap/Sales(5y)29.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.22%
EPS Next Y0%
EPS Next 2Y17.26%
EPS Next 3Y17.57%
EPS Next 5YN/A
Revenue 1Y (TTM)-42.65%
Revenue growth 3Y-1.34%
Revenue growth 5Y1.53%
Sales Q2Q%-44.77%
Revenue Next Year-29.35%
Revenue Next 2Y10.07%
Revenue Next 3Y16.54%
Revenue Next 5YN/A
EBIT growth 1Y-27.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-49.54%
EBIT Next 3Y8.56%
EBIT Next 5YN/A
FCF growth 1Y-91.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-75.44%
OCF growth 3YN/A
OCF growth 5YN/A